Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
US8815258 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
US11833292 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(14 years from now) | |
US11331442 | ASTRAZENECA AB | Drug delivery systems and related methods |
Oct, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Jul 23, 2023 |
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION